Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Glioblastoma multiforme
ADR ID BADD_A01843
ADR Hierarchy
17      Nervous system disorders
17.20      Nervous system neoplasms malignant and unspecified NEC
17.20.02      Glial tumours malignant
17.20.02.001      Glioblastoma multiforme
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.30      Nervous system neoplasms malignant and unspecified NEC
16.30.02      Glial tumours malignant
16.30.02.001      Glioblastoma multiforme
Description A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. [MeSH]
MedDRA Code 10018337
MeSH ID D005909
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Glioblastoma multiforme | Glioblastoma | Glioblastomas | Astrocytoma, Grade IV | Astrocytomas, Grade IV | Grade IV Astrocytoma | Grade IV Astrocytomas | Glioblastoma Multiforme | Giant Cell Glioblastoma | Giant Cell Glioblastomas | Glioblastoma, Giant Cell | Glioblastomas, Giant Cell
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00497Clomiphene--
BADD_D00498Clomiphene citrate--
BADD_D00511Clozapine0.001834%
BADD_D00858Everolimus0.000153%
BADD_D01253Lenalidomide0.000603%
BADD_D02150Temozolomide0.001421%
BADD_D02165Teriflunomide0.000241%
BADD_D02236Tofacitinib0.000241%
BADD_D02464Fingolimod0.000482%
BADD_D02524Ivosidenib0.000112%
BADD_D02526Larotrectinib0.000168%
The 1th Page    1    Total 1 Pages